Breast cancer patients with a high Recurrence Score were more likely to have a complete response following Taxotere® than women with a low Recurrence Score. These findings were presented at the 2006 annual meeting of the American Society of Clinical Oncology held in Atlanta, Georgia, June 2-6, 2006.
Although adjuvant chemotherapy has been shown to benefit some women with early-stage or locally advanced breast cancer, some patients are already at enough of a low risk of cancer recurrence that the additional side effects are not warranted. Identifying which patients are most likely to benefit from treatment may reduce unnecessary treatment and toxicity.
Oncotype DX is a genomic test that may be useful in determining which patients with newly diagnosed, stage I or II, node-negative, estrogen receptor-positive breast cancer may benefit from adjuvant chemotherapy in addition to hormonal therapy. Oncotype DX predicts the risk of a patient experiencing a recurrence 10 years following diagnosis. Oncotype DX evaluates the activity of 21 genes from a sample of the patient’s cancer to determine the patient’s Recurrence Score. The Recurrence Score ranges from 0 to 100, with a higher score indicating a greater risk of recurrence.
Researchers from the Baylor-Methodist Breast Care Center and Genomic Health conducted a clinical trial involving 72 patients with locally advanced breast cancer to determine if genetic features of their cancer may predict whether they will respond to treatment with neoadjuvant Taxotere. Average patient age was 49 years, 53% were premenopausal, and 93% had invasive ductal carcinoma.
The researchers evaluated each patient’s cancer to evaluate the activity of 192 genes and determine whether the expression of any of these genes may predict response to Taxotere. Expression of 14 of these genes was associated with a higher likelihood of experiencing a complete response to Taxotere.
Furthermore, the researchers reported that women classified as high risk based on the Recurrence Score were more likely to respond to neoadjuvant Taxotere® than women classified as low risk.
None of the patients who were classified as low-risk of recurrence-based on their Recurrence Score-experienced a complete anticancer response, while three (14%) of the intermediate-risk women and nine (21%) of the high-risk patients experienced complete response to neoadjuvant Taxotere.
Patients with early-stage or locally advanced breast cancer should talk to their doctor about the Oncotype DX genomic test. For these patients, knowing their Recurrence Score may direct their treatment, as this information identifies their individual risk for recurrence and likelihood of benefiting from adjuvant chemotherapy.
Reference: Chang JC, Makris A, Hilsenbeck SG et al. Gene Expression Profiles in Formalin-Fixed, Paraffin-Embedded (FFPE) Core Biopsies Predict Docetaxel Chemosensitivity. Proceedings of the 42nd Annual Meeting of the American Society of Clinical Oncology. Atlanta, GA. 2006. Abstract # 538.
Oncotype DX Predicts Chemotherapy Response in Early Breast Cancer (5/26/2006)
Copyright © 2018 CancerConnect. All Rights Reserved.